Katie Rielly-Gauvin is Vice President of Global Commercial Development at AbbVie, a global biopharmaceutical company, where she is responsible for developing the strategic commercial direction of key compounds in AbbVie's pipeline across core therapeutic areas in Immunology, Oncology, Neuroscience and Specialty. She brings more than 20 years of a broad range of business experiences in the pharmaceutical industry.
Prior to joining AbbVie, Katie was at Johnson & Johnson where she was Vice President, Redscript Ventures, a Johnson & Johnson business accelerator created purposely for shaping new, venture stage business investments. Prior to this role, she was Vice President and General Manager for the Janssen Commercial CNS organization, where she was responsible for a $3.0B product portfolio.
She began her career at Johnson & Johnson family of companies in 1993, where she worked as Manager of Infectious Disease Research at Ortho-McNeil and held positions of increasing responsibility in Medical Affairs and the Commercial organizations. Katie began her career with Bristol-Myers Squibb as a Research Scientist in clinical drug development.
Katie holds a Bachelor of Science degree in Chemistry from Simmons College and an MBA in Economics from Rutgers University. She currently serves as Board Chairman of the Preeclampsia Foundation.